![]() 2006 23(7):883–93.Ĭholongitas E, Marelli L, Kerry A, Goodier DW, Nair D, Thomas M, Patch D, Burroughs AK. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. 2011 23(1):51–9.Ĭholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G, Shaw S, Burroughs AK. Mortality after surgery in patients with liver cirrhosis: comparison of Child-Turcotte-Pugh, MELD and MELDNa score. 1964 1:1–85.Ĭho HC, Jung HY, Sinn DH, Choi MS, Koh KC, Paik SW, Yoo BC, Kim SW, Lee JH. Predicting mortality across a broad spectrum of liver disease – an assessment of Model for End-Stage Liver Disease (MELD), Child–Turcotte–Pugh (CTP), and creatinine-modified CTP scores. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. 2003 52(1):134–9.Ĭhalasani N, Kahi C, Francois F, Pinto A, Marathe A, Bini EJ, Pandya P, Sitaraman S, Shen J. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. 2012 18(11):1302–9.īotta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R. Exception point applications for 15 points: an unintended consequence of the share 15 policy. Evidence-based incorporation of serum sodium concentration into MELD. 2005 41(1):32–9.īiggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Serum sodium predicts mortality in patients listed for liver transplantation. 2011 46(7–8):941–8.īiggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Impact of the MELD allocation after its implementation in liver transplantation. 1996 23(1):164–76.īenckert C, Quante M, Thelen A, Bartels M, Laudi S, Berg T, Kaisers U, Jonas S. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. 1982 143(1):55–60.Īrroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J. Cholecystectomy in cirrhotic patients: a formidable operation. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. 2009 87(5):1460–8.Īlessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P. Model for end-stage liver disease predicts mortality for tricuspid valve surgery. 2007b 146(10):707–13.Īilawadi G, LaPar DJ, Swenson BR, Siefert SA, Lau C, Kern JA, Peeler BB, Littlewood KE, Kron IL. Differences in access to liver transplantation: disease severity, waiting time, and transplantation center volume. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Model for end-stage liver disease (MELD) scoreĪhmad J, Downey KK, Akoad M, Cacciarelli TV. ![]() The MELD score is not an accurate biomarker for the risk of death from liver cancer and some other conditions, and hence for the purposes of liver allocation on the transplant list, an exception to the calculated MELD score can be given. Since the MELD score was introduced, there have been several modifications that may have increased effectiveness in certain situations. The MELD score has been adopted as a biomarker with good effect in other situations where patients with ESLD have a high risk of dying such as surgery, alcoholic hepatitis, acute liver failure, and variceal bleeding. ![]() The use of the MELD allocation system has resulted in sicker patients being transplanted with decreased waiting time, thereby decreasing the death rate on the LT waiting list, without an adverse effect on posttransplant outcome. Since 2002, the MELD score has been used to prioritize deceased donor organ allocation for patients listed for liver transplantation (LT) in the USA. The MELD score incorporates serum bilirubin, creatinine, and INR in a mathematical formula. The model for end-stage liver disease (MELD) score was developed and is an accurate biomarker of 90-day mortality in patients with ESLD, essentially measuring how sick a patient is. Previous methods to quantify the risk of death in these patients were subjective. End-stage liver disease (ESLD) due to cirrhosis carries a high mortality. ![]()
0 Comments
Leave a Reply. |